Emily Gaudiano, Ph.D.

Dr. Emily Gaudiano is responsible for investment identification, due diligence, business development, and company creation activities at MPM and BioImpact Capital, an affiliate manager of MPM. Emily joined MPM full time in 2022 after completing an internship with the firm, where she supported diligence efforts for MPM newco Aktis Oncology and surveyed incoming deal flow for investment opportunities.

Prior to joining MPM and BioImpact Capital, Emily was recently awarded her Ph.D. in Chemical Biology at Harvard Medical School under advisor Arlene Sharpe. Her thesis focused on characterizing novel signaling mechanisms of co-inhibitory receptor PD-1 in tumor infiltrating lymphocytes. In addition to her academic research, Emily served as a director on the leadership team of the GSAS Harvard Biotech Club and has been involved in a variety of community outreach programs across Boston to address healthcare disparities.

Emily received her B.S. in Biochemistry from Boston College.

Rami Rahal, Ph.D.

Dr. Rami Rahal is responsible for investment identification and due diligence for BioImpact Capital, an affiliate manager of MPM.

Prior to joining BioImpact Capital, Rami spent the majority of his career in drug discovery prosecuting multiple target classes for both precision oncology and immunotherapy.  Most recently, he was a Senior Director of Cancer Biology at Scorpion Therapeutics where he joined as the first biologist and played pivotal roles in expanding the biology drug discovery team, research infrastructure, and early portfolio.   Before joining Scorpion Therapeutics, Rami was at KSQ Therapeutics, where he led multiple small molecule drug discovery programs for novel IO targets and helped build an integrative IO drug discovery strategy.  Rami began his career in biotech at Blueprint Medicines where he served as the lead biologist for the RET inhibitor program (BLU-667/Pralsetinib) from early optimization into Phase 1.  Pralsetinib is now an FDA approved medicine (Gavreto) for RET-driven metastatic NSCLC and medullary thyroid cancer.

Rami earned his PhD in Genetics from MIT and conducted postdoctoral fellowships at Harvard Medical School and the Novartis Institutes of Biomedical Research (NIBR).  At NIBR, he leveraged pharmacological and genomic profiling to identify new treatment strategies for mantle cell lymphoma and characterized novel synthetic lethal cancer vulnerabilities.  His work has been highlighted in Cancer Cell, Cancer Discovery, and Nature Reviews Cancer.

Alim Ladha, Ph.D.

Dr. Alim Ladha is responsible for investment identification, due diligence, business development, and company creation activities at MPM and BioImpact Capital, an affiliate manager of MPM.

Prior to joining MPM and BioImpact Capital, Alim completed his Ph.D. in Biological Engineering at the Massachusetts Institute of Technology (MIT) in Feng Zhang’s lab at the Broad Institute where he focused on developing new molecular tools for biotechnology including CRISPR-associated transposases, retroelement based genome insertion methods, novel nucleic acid delivery vehicles, and CRISPR-based diagnostics.  Prior to MIT, Alim worked on the development of microbiome-based therapeutics at Finch Therapeutics and OpenBiome.

Alim received his B.S.E., summa cum laude, in Biomedical Engineering from Duke University.

Uciane Scarlett, Ph.D.

Dr. Uciane Scarlett is responsible for investment identification, due diligence, business development and new company creation activities at MPM and BioImpact Capital, an affiliate manager of MPM. Uciane currently serves on the board of a newly formed, stealth portfolio company.

Prior to joining MPM and BioImpact Capital, Uciane was a Principal at Oxford Sciences Enterprise (OSI, UK), an Oxford-affiliated firm, where she initially co-led the life science sector. While at OSE, Uciane led financings and drove company creation efforts for several companies including T-Cypher Bio, where she served as interim Executive Chair, Alethiomics, PepGen and Endlyz. She represented OSE on the boards of T-Cypher, PepGen, Miro Bio, Scenic Bio, and DJS. Prior to OSE, Uciane was on the investment team at Atlas Venture where she drove company creation, operations, and financings activities for Dyne Therapeutics (DYN) and Quench Bio and served in operational roles for AVROBIO (AVRO) and KorroBio. Uciane was the Director of BD & Strategy at Compass Therapeutics prior to Atlas.

Uciane holds a Ph.D. in cancer immunology from Dartmouth College. She received her BSc, first-class honors, in biotechnology (major) and zoology (minor) from the University of the West Indies.

Jeff Crispen

Jeff Crispen is the Chief Financial Officer of BioImpact Equities (f/k/a Burrage Capital).

Previously Jeff served as the Chief Operating Officer, Chief Financial Officer, and Chief Compliance Officer at Cambridge Square Capital, a Boston-based relative-value volatility arbitrage hedge fund he helped launch in 2016.  Prior to that, he was the Chief Operating Officer and Chief Financial Officer for Feingold O’Keeffe Capital (later sold to NewStar Financial), a Boston-based multi-product alternative credit manager and previously the Chief Financial Officer for Boldwater Capital Management.

Jeff began his career as an auditor at Arthur Andersen, and later joined the Cayman Islands office of Ernst & Young.  Jeff then joined Deloitte as a senior manager in their investment management practice.

Jeff earned his B.S.  in Business Administration with a concentration in accounting with honors from the University of Connecticut.

Christian Desmarteaux, M.B.A.

Christian Desmarteaux is the Director of Investor Relations for BioImpact Equities (f/k/a Burrage Capital) and is responsible for coordinating all efforts relating to both existing and prospective investor relations.

Prior to joining Burrage Capital, Christian was an Account Executive at Turbonomic, a Boston based technology firm that is a global leader in business application performance.  Prior to that, he worked as a Sales Consultant raising capital for several privately held companies in North America to help them achieve strategic business development and capital milestones.

Christian earned his M.B.A. from Northeastern University D’Amore-McKim School of Business and his B.S. in Communication/Business Administration from St. John’s University.

Terri Lee, Ph.D.

Dr. Terri Lee is responsible for investment identification, due diligence and business development activities at MPM. Currently, she serves as Interim Director of Strategy and Operations at a newly formed, stealth MPM startup company.

Recently awarded her Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, Terri’s thesis focused on the role of actin nucleators in DNA repair pathways. In addition to academic research, Terri worked on identifying commercial opportunities and company formation at the Gladstone Institutes, including taking on an operations role at a therapeutics company in the neurodegenerative space.

Terri received her B.S. in Pharmacology and Microbiology from the University of California, Santa Barbara.

Kellie Neville

Kellie Neville is the Director of Investor Relations at MPM Capital. She joins MPM’s Managing Directors in building lasting relationships with its Limited Partners.  Kellie also leads MPM’s communications and marketing efforts.

Prior to joining MPM, Kellie was Director of Investor Relations & Marketing at 424 Capital, a boutique private equity investor, where she was responsible for raising capital, investor relationships and product development. Prior to that, Kellie was a Senior Investor Relations Associate at TA Associates, a middle market growth equity partner, supporting the firm’s fundraising efforts and ongoing Limited Partner relationships.

Kellie earned her B.A. in Public Relations and Marketing Communications from Simmons University.

Brian Goodman, Ph.D.

Dr. Brian Goodman is responsible for investment identification, due diligence, business development and new company creation activities at MPM and BioImpact Capital, an affiliate manager of MPM. Brian is a co-founder of Aktis Oncology and a member of the Board of Directors of Orna Therapeutics.  He has also played key leadership roles at portfolio companies during the early stages of development, including at Orna Therapeutics in Business Development and at Aktis Oncology as Chief Operations Officer.

Prior to joining MPM and BioImpact Capital, Brian co-founded Evelo Biosciences (NASDAQ: EVLO) and served as Head of Technology and Innovation. At Evelo, Brian led a team that established new programs to discover, formulate, and evaluate the pharmacology of microbial drugs across multiple therapeutic areas. He contributed to the in-licensing of foundational IP and forged collaborative research with multiple academic groups to complement Evelo’s internal research and development efforts. He is an inventor on multiple patent applications. Before taking the operational role at Evelo, Brian was a Senior Associate at Flagship Pioneering where he worked with the entrepreneurial division to build and launch new biotech ventures.

Brian holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School, and B.S. and B.A. degrees in biochemistry and economics, respectively, from Brandeis University.

Devin Quinlan, Ph.D.

Dr. Devin Quinlan is responsible for investment identification, due diligence, business development, and company creation activities at MPM and BioImpact Capital, an affiliate manager of MPM. Devin joined MPM full time in 2018 after completing an internship with the firm and has since supported multiple investments across diverse therapeutic areas, including MPM’s investments into Orna Therapeutics and Triplet Therapeutics. Devin was also part of the founding team of a stealth oncology NewCo, where he is Head of Strategy & Operations and a Board Observer.

Prior to joining MPM and BioImpact Capital, Devin completed his Ph.D. in Biological Engineering at the Massachusetts Institute of Technology (MIT) under advisor Ram Sasisekharan. His thesis was focused on uncovering structure-function relationships of antibodies which target viral antigens, including Ebola and Zika viruses. In addition to his academic research, Devin served as part of the inaugural leadership team of the MIT Biotech Group, which has since grown into the largest life-sciences student organization at MIT.

Devin received his B.S. in Bioengineering from the University of California, Los Angeles.